Series B · Raised $46M · Aug 7, 2026announcement ↗
Mironid
Backed by
BiotechGlasgow, United Kingdommironid.com ↗
What they do
Mironid is a Glasgow-based biopharmaceutical company developing small-molecule therapeutics for rare genetic and degenerative kidney diseases. Its lead focus is autosomal dominant polycystic kidney disease (ADPKD), with programmes targeting cAMP-degrading phosphodiesterase enzymes.
Hiring outlook
A $46 million Series B should support clinical development and expansion of the drug pipeline. The company may add clinical development, regulatory, translational science, pharmacology, and biopharmaceutical operations staff, along with supporting commercial and corporate roles as programmes advance.
Open roles
No open roles on their board right now.